Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US
Journal article published in 2024 by
Christina Waldron 
,
Satoko Ito,
Daniel Wang ,
Cecily Allen ,
Giri Viswanathan,
Robert D. Bona ,
Adam Cuker ,
George Goshua
,
Satoko Ito,
Daniel Wang ,
Cecily Allen ,
Giri Viswanathan,
Robert D. Bona ,
Adam Cuker ,
George Goshua
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
We evaluated the cost-effectiveness of prophylaxis with rVWF versus with pdVWF for patients with severe VWD. We found that rVWF is a cost-saving factor replacement compared to pdVWF across all willingness-to-pay thresholds in the United States.